News for Ocugen, Inc. (OCGN)

OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ETCompany ParticipantsTiffany Hamilton - Head, Corporate...

Conference Call and Webcast Today at 8:30 a.m. ET Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt di

Quarterly Revenue: $0.76 million, surpassing the estimated $0.30 million.Quarterly EPS: Reported a net loss of $0.05 per share, matching the estimated loss of

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) —

Ocugen (OCGN) said it has reached an alignment with the FDA for a Phase 2/3 study that could be used to support approval of its gene therapy OCU410ST for Stargardt disease.

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a pioneering biotechnology leader in gene therapies for blindnes

Atkore Inc. (NYSE: ATKR):

**media[546596]**

Ocugen (OCGN) said it has received a positive opinion from EU regulators for Advanced Therapy Medicinal Product classification for its gene therapy OCU400. Read more here.

OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clini

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (”œOcugen” or the ”œCompany”) ( OCGN), a biotechnology company focused on discovering, deve

100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9

**media[513301]**

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a biotechnology company focused on discovering, developing, and

MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a biotechnology company focused on discovering, developing, and

Ocugen (OCGN) reported positive Phase 1 data for its gene therapy candidate OCU410 in the treatment of geographic atrophy. Read more here.

Ocugen (OCGN) delivered earnings and revenue surprises of 0% and 5.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Cash and Restricted Cash: $39 million as of September 30, 2024, compared to $39.5 million as of December 31, 2023.Total Operating Expenses: $14.4 million for t